Track AIM ImmunoTech Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

AIM ImmunoTech Inc. AIM · Stock Open AIM ImmunoTech Inc. in new tab

0.1877 USD
Add to portfolio
EPS
-0.71
P/B
0.71
ROE
-2382.30
Beta
1.19
Target Price
4.25 USD
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateNov. 16, 2026
EPS-0.71
Book Value0.27
Price to Book0.71
Debt/Equity50.63
% Insiders0.742%
Growth
Revenue Growth0.04%
Estimates
Forward P/E-0.51
Forward EPS-0.37
Target Mean Price4.25

DCF Valuation

Tweak assumptions to recompute fair value for AIM ImmunoTech Inc. (AIM)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

AIM ImmunoTech Inc. Logo AIM ImmunoTech Inc. Analysis (AIM)

United States Health Care Official Website Stock

Is AIM ImmunoTech Inc. a good investment? AIM ImmunoTech Inc. (AIM) is currently trading at 0.1877 USD. Market analysts have a consensus price target of 4.25 USD. This suggests a potential upside from current levels.

Earnings Schedule: AIM ImmunoTech Inc. is expected to release its next earnings report on Nov. 16, 2026. The market consensus estimate for Forward EPS is -0.37.

Investor FAQ

Does AIM ImmunoTech Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is AIM ImmunoTech Inc.?

AIM ImmunoTech Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Nov. 16, 2026. The company currently has a trailing EPS of -0.71.

Company Profile

AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.

Exchange Ticker
ASE (United States) AIM
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Aug. 29, 2016 0.08
June 11, 2019 1:50
June 12, 2025 1:100
Feb. 10, 2026 1.03
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion